Skip to main content

Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single‐centre study

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Abstract

Experience in the treatment of patients with acute promyelocytic leukaemia (APL) and accelerated phase chronic myeloid leukaemia with orally administered arsenic trioxide (ATO) in our institution since 1999 has demonstrated that bioavailability of oral ATO is comparable with intravenous administration, and similar outcomes are produced in treatment of APL. Oral administration was well tolerated, with good compliance, in patients not requiring hospitalisation for postinduction treatment and was particularly convenient for patients living considerable distances from our institution. Orally administered ATO can be considered a practicable option in management of APL.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1445-5994.2012.02852.x

Affiliations: Departments of Medicine and Clinical Haematology, St. Vincent's Hospital, Melbourne, Victoria, Australia

Publication date: August 1, 2012

bsc/imj/2012/00000042/00000008/art00017
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more